Shares of Global-e Online Ltd. (GLBE) have gained 2.2% over the past four weeks to close the last trading session at $34.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $48.92 indicates a potential upside of 41.2%.The mean estimate comprises 13 short-term price targets with a standard deviation of $6.93. While the lowest estimate of $40.00 indicates a 15.5% increase from the ...

U.S. Physical Therapy (USPH) closed the last trading session at $83.25, gaining 1.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $105.33 indicates a 26.5% upside potential.The average comprises six short-term price targets ranging from a low of $98.00 to a high of $113.00, with a standard deviation of $5.92. While the lowest estimate indicates an increase of 17.7% from the curr ...

Monro Muffler Brake (MNRO) closed the last trading session at $20.07, gaining 6.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.63 indicates a 27.7% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $10.08. While the lowest estimate of $17.50 indicates a 12.8% decline from the current price level, the most optimistic anal ...

分组1 - Evolus, Inc. reported quarterly earnings of $0.06 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.01 per share a year ago [1] - The company posted revenues of $90.3 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 0.98% and up from $78.95 million year-over-year [2] - Evolus shares have declined approximately 35.5% since the beginning of the year, contrasting with the S&P 500's gain of 0.5% [3] 分组2 - The earnings outlook for Evolus is uncertain, with current consensus EPS estimates at -$0.11 for the coming quarter and -$0.04 for the current fiscal year, alongside revenues of $71.74 million and $330.94 million respectively [7] - The Zacks Industry Rank indicates that the Medical - Products sector is in the bottom 41% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8] - The estimate revisions trend for Evolus was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6]

Shares of Replimune Group, Inc. (REPL) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $12.86 indicates a potential upside of 79.6%.The average comprises seven short-term price targets ranging from a low of $10.00 to a high of $19.00, with a standard deviation of $3.02. While the lowest estimat ...

Prothena (PRTA) closed the last trading session at $9.4, gaining 5.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $20.5 indicates an 118.1% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $10.65. While the lowest estimate of $8.00 indicates a 14.9% decline from the current price level, the most optimistic analyst expects th ...

Core Insights - AutoZone reported quarterly earnings of $27.63 per share, exceeding the Zacks Consensus Estimate of $27.1 per share, but down from $28.29 per share a year ago, resulting in an earnings surprise of +1.94% [1] - The company generated revenues of $4.27 billion for the quarter, missing the Zacks Consensus Estimate by 0.82%, compared to $3.95 billion in the same quarter last year [2] - AutoZone's stock has increased by approximately 14.5% year-to-date, significantly outperforming the S&P 500's gain of 0.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $36.30, with expected revenues of $4.83 billion, and for the current fiscal year, the EPS estimate is $148.80 on revenues of $20.48 billion [7] - The trend of earnings estimate revisions for AutoZone was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Automotive - Retail and Wholesale - Parts industry, to which AutoZone belongs, is currently ranked in the bottom 20% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Shares of BioLife Solutions, Inc. (BLFS) have gained 11% over the past four weeks to close the last trading session at $24.2, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $32.67 indicates a potential upside of 35%.The mean estimate comprises nine short-term price targets with a standard deviation of $1. While the lowest estimate of $31.00 indicates a 28.1% increase from the c ...

Shares of HCI Group (HCI) have gained 11.2% over the past four weeks to close the last trading session at $176.42, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $231.67 indicates a potential upside of 31.3%.The average comprises three short-term price targets ranging from a low of $205.00 to a high of $255.00, with a standard deviation of $25.17. While the lowest estimate indi ...

Shares of Slide Insurance Holdings, Inc. (SLDE) have gained 10.3% over the past four weeks to close the last trading session at $19, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $24.4 indicates a potential upside of 28.4%.The mean estimate comprises five short-term price targets with a standard deviation of $2.88. While the lowest estimate of $22.00 indicates a 15.8% increase ...